Breakthrough Agents Reshaping RRMM Treatment Landscape

Noa Biran, MD, reviews approved bispecific T-cell engagers and how they redefine multiple myeloma treatment, yielding high response rates in refractory cases, but their use necessitates careful evaluation in later therapy lines.

EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma

Now Viewing

EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape

EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen

EP: 4.Examining Selinexor Role in RRMM Treatment

EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo

EP: 6.Sequencing Selinexor With Novel BCMA Therapies

EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being

EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Recent Videos

Related Content

---

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy

March 4th 2024

Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Related Content

---

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy

March 4th 2024

Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.